Introduction
Recurrent seizures represent an important clinical manifestation of neurological disease in HIV infection. Frequency rates of 3-11% have been reported in hospital based studies of HIV infected individuals. [1] [2] [3] [4] [5] [6] The aetiology of seizures in HIV-infected individuals include opportunistic infections, neoplasia, HIV itself, metabolic derangements and drugs. [1] [2] [3] [4] [5] [6] Apart from identifying and treating the underlying cause of the seizures, the challenge is to use the appropriate anticonvulsant (AED) in patients who are on highly active anti-retroviral therapy (HAART). Protein binding and metabolism via cytochrome P450 system could lead to adverse drug-drug interaction and loss of viral suppression. Initial recommendations were that the newer AEDs such as gabapentin, levetiracetam and tiagabine should preferably be used as they have simpler pharmacokinetics than the older AEDs such as phenytoin and carbamazepine. 7, 8 The same authors advised caution with the use of valproate/valproic acid (SV/VA) as, in vitro studies suggested that this drug promoted viral replication. 9, 10 We report on the clinical and laboratory findings of eight patients who were on concurrent sodium valproate (SV) and HAART.
Methods and case studies
HIV positive patients on HAART who developed new onset seizures were recruited for the study. Patients or their guardians who gave consent were included in the study. Exclusion criteria included known allergy to SV, hepatic enzymes greater than 10 times the upper limit of normal, a prothrombin time that was 5 or more seconds than the control value, and pregnancy. The study was approved by the Bioethics Committee of the University of KwaZulu-Natal.
All patients underwent a complete clinical examination. At baseline the following routine blood investigations were done: full blood count (FBC), urea and electrolytes (U&E), liver function tests (LFTs), glucose, calcium, magnesium, phosphate, international normalised ratio (INR), rapid plasma reagin (RPR) and antinuclear factor (ANF). CD4 counts and viral loads were measured at baseline and at approximately 2-6 month intervals. All patients had a chest radiograph and either a CT or MRI scan of the brain. If indicated, cerebrospinal fluid was subjected to routine chemistry, microscopy, bacterial and fungal culture, viral polymerase chain reaction studies, cryptococcal antigen and cytological examination.
According to the South African national guidelines for HAART, all except one patient were on either regimen 1a (Stavudine, Recurrent seizures may occur in up to 11% of HIV positive patients. The aetiology of the seizures includes opportunistic infections, neoplasia, HIV itself, metabolic derangements and drugs. Apart from treating the cause of the seizures, the challenge is to use the appropriate anticonvulsant drug (AED) to avoid potentially adverse drug-drug interactions in patients who are on concurrent highly active antiretroviral therapy (HAART). Initial recommendations were that the newer AEDs should preferably be used because of their simpler pharmacokinetics.
We report on our experience with the use sodium valproate (SV) in eight patients who were on concurrent HAART. There were two males and six females with a mean age of 34.1 years. The mean dose of SV was 1075 mg per day. Seizure control was excellent, the CD4 count improved and there was successful viral suppression in all patients.
This small study showed that SV was safe and effective. It is also relatively inexpensive compared to the newer AEDs -an important consideration in resource poor settings.
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Lamivudine and Efavirenz) or 1b (Stavudine, Lamivudine and Nevirapine).
Results
The clinical and radiological data are summarized in Table 1 . The duration of follow up after institution of AEDs, the CD4 counts and viral loads are summarized in Table 2 . There were two males and six females with a mean age of 34.1 years (range 12-45). The duration of HAART therapy ranged from 0 to 13 months prior to commencements of SV. The mean daily dose of SV was 1075 mg (range 600-2000 mg). The duration of follow up after initiation of SV ranged from two to thirty nine (mean of 15) months. The aetiology of seizures was tuberculosis in two patients. Patient 2 with brain tuberculomata presented with seizures and was commenced on ARVs at seizure onset. Patient 8 was diagnosed with TB meningitis a month after ARV initiation. An IRIS phenomenon was considered. Both patients were given standard 4 drug antituberculous therapy together with a month of prednisone at 40 mg daily. Patient 1 had lamotrigine (25 mg bd) and patient 8 had gabapentin (300 mg tds) added to their treatment. Four became seizure free, one had the occasional seizure, two had a single seizure each in 6 months and 1 had a seizure in 2 months of follow up. The mean CD4 count at baseline was 187 with a range from 2 to 550. The CD4 count improved in all patients. The viral load was suppressed in all patients.
Discussion
Potential adverse drug-disease and drug-drug interactions in HIV infected individuals have been reported in isolated case studies. As many as 14% of HIV seropositive patients on phenytoin had hypersensitivity reactions.
1 Drugs such as phenytoin, carbamazepine and phenobarbitone may increase the metabolism of the protease inhibitors (PI) and result in loss of viral suppression. 11 Conversely, inhibition of the CYP 450 enzyme system by the PIs may lead to toxic levels of phenytoin and carbamazepine. 12 Factors such as these, as well as the concern that SV/VA may increase viral replication 9, 10 led to the earlier recommendation that the older AEDs should be avoided in HIV seropositive patients who were on HAART.
Although there are no large prospective studies examining drug-drug interactions, the earlier concern about SV/VA has not been confirmed by more recent studies. Maggi and Helman 13 did not find increased viral loads in six patients taking valproate. In fact a proof of concept study suggested that the addition of valproic acid to HAART may be beneficial in depleting latent HIV infection. 14 Although, this concept was not confirmed, 15, 16 these studies did show that SV/VA was safe. Our small study confirms the efficacy and safety of SV/VA in HIV seropositive patients on HAART. In all patients there was a rise in CD4 counts and adequate viral suppression. None of our patients was on zidovudine whose bioavailability (and hence side effects) is increased in the presence of SV/VA.
14 Nor was any patients on PIs.
The data on PIs and SV/VA is scanty but close monitoring is advised. 17 
Conclusion
There is little information about the combination of HAART and newer AEDs. Locatelli et al. 18 studied seven patients on HAART and
Leviteracetam. The combination was safe and effective. Despite the initial call for use of the newer AEDs for patients on HAART because of their (AEDs) simpler pharmacokinetics, the data on the newer AEDs is limited. There is the additional aspect of the cost of the newer AEDs -an important consideration in resource poor settings. Currently, there is increasing evidence that SV/VA can be used safely and effectively in patients who are on HAART. Table 1 Clinical and radiological data. Patient 4 was followed up as part of another trial using a different regimen -tenofovir, emtricitabine and efavirenz. 1a = stavudine, lamivudine and efavirenz. 1b = stavudine, lamivudine and nevirapine. Table 2 The duration of follow up on AEDs and HAART, the CD4 counts and viral loads. Patient 4 was part of another trial where the viral load cut off value was <400 copies/ml. ND = not done due to technical difficulties. Patient 5 had a baseline CD4 value >200 as the CD4 percentage rather than absolute CD4 value is used in paediatric ARV clinics as a criteria for initiation of ARVs. Patient 7 was re-instated on ARVs following a 6 month default and the baseline CD4 represents the point of reinitiation. 
